Action in Diabetes

Read more about the ADVANCE trial on The George Institute website

A factorial, randomised controlled trial study designed to determine the effects of intensive blood pressure lowering and glucose control on cardiovascular risks among type 2 diabetes patients. Covering both advanced economies in North America and Western Europe and emerging economies in Eastern Europe and Asia. 

Impact

Sites contributing to the ADVANCE Study included 20 countries, 216 centres and 11,140 patients. ADVANCE had eighteen months for recruitment, an average of five years follow-up and achieved database lock in nine days. Results have been published in The Lancet and The New England Journal of Medicine.